Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CTEC: Cholestech any other investors? -- Ignore unavailable to you. Want to Upgrade?

To: John Kratus who wrote (352)	12/12/1997 9:52:00 AM
From: Duane L. Olson	Respond to of 710

John, I hope all the CTEC-ers will read your excellent summary of the fundamentals. They are compelling. I preceded you into another CTEC purchase by picking up shares at 10 1/4.. I will average down if the market insanity offers further opportunities for bargains. For the time being, I'm afraid, the herd mentality has shifted in the market to a focus on the severity of the SEA turmoil. So fundamentals will likely get short shrift for the time being. Even for companies little affected by the turmoil. Thanks so much for keeping the CTEC story updated, and foremost in the thread.. Certainly CTEC is going to be higher in future years, and I 'd be disappointed to miss it. dlo

To: John Kratus who wrote (352)	12/13/1997 5:52:00 PM
From: mike boyajian	Read Replies (2) \| Respond to of 710

John, The pharmacy sales are the key to success and the only reason that the stock made it to $15. Exponential growth is only possible through rapidly increasing the installed base of LDX machines. The FY 99 estimate of $.34 to $.60 is predicated on having an installed base of some 15,000 machines. They currently have approximately 7600 at end of last quarter. The analyst from Principal Financial based his projections on this 15K number of machines. Also, I had understood that the 1000 machines sold to Parke-Davis were booked in last QTR's revenue thus explaining why the net income was 100% over the analysts estimates ($.04 vs $.02). Sales of cassettes to support these machines of course will be booked as they are sent to the user. If the pharmacy sales are not happening now I think this next QTR will be $.04 (if we are lucky). Hopefully it will be higher but I doubt it without the new pharmacy market. Of course Lola laughed when you asked her about the World Health Organization deal. Did you expect her to pass along insider information if this deal is in the works? Maybe Alexa can fill in some blanks for us on future markets. If this company is to be successful long term that will: 1. Have to increase the installed base of machines substantially and 2. Continue to develop and receive approval for use of additional test cassettes. Mike